Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized placebo-controlled study of SP16 for ischemia-reperfusion injury after PCI in STEMI
MOH_2026-06-07_016868Phase 2Not yet recruiting
- Sponsor
- Serpin Pharma
- Start
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in myocardial ischemia-reperfusion injury comparing SP16 with Placebo (2 arms). Primary endpoint: Cardiac MRI assessment of myocardial injury. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SP16
03
Conditions
myocardial ischemia-reperfusion injury
Beyond the preview
Go deeper on MOH_2026-06-07_016868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-07_016868.